Dapagliflozin for Type 2 Diabetes

"This 16-week clinical trial aims to observe the effect of Dapagliflozin plus exenatide (Bydureon) on Endogenous Glucose Production. Secondary objectives include comparing Change in EGP for Exenatide (Byetta), Dapagliflozin, and Dapagliflozin/Exenatide versus Placebo."

"This medical investigation is seeking 88 individuals aged 18 to 70 with diabetes mellitus, type 2. Additionally, it's essential that applicants possess the following criteria: BMI 25-35 kg/m^2; minimal fluctuation in body weight over the prior three months; and overall good health based on physical examination, patient history, bloodwork analysis, CBC count, TSH level detection, thyroid hormone measure (T4), electrocardiogram readout and urinalysis results."

"Our team of experts rated the safety of this combination therapy at a 3, given that it is already approved and available for clinical use."

"Byetta/Bydureon plus Dapagliflozin can be employed for pharmaceutical preparations, as well as supplemental interventions like diet and exercise when monotherapy is deemed insufficient."

"Adhering to the study criteria, individuals must be at least 18 years old and no older than 70 in order to take part."

"As per the information on clinicaltrials. gov, this trial is not open to new participants as of now; however, it was first listed in December 2017 and last updated in September 2022. Despite being closed for recruitment at present, there are 1592 other trials recruiting patients presently."

"This particular trial is not presently registering patients. Initially posted on December 15th 2017 and most recently updated on September 12th 2022, it has ceased accepting candidates. If you are still in search of research studies to join, there are currently 1,512 medical trials recruiting diabetics type 2 and 80 other investigations that study the effects of Byetta/Bydureon paired with Dapagliflozin."

"Presently, 80 clinical trials for Byetta/Bydureon plus Dapagliflozin are taking place across 239 cities and 50 nations. The first iteration of this drug trial was conducted in 2007 by CellTrans Inc., involving a cohort of 21 patients that successfully completed Phase 3 regulatory approval. Since then, 18618 studies have been concluded."